首页> 美国卫生研究院文献>Health Science Reports >Long‐term clinical outcome and mortality risks after paclitaxel‐coated balloon angioplasty in patients with peripheral artery disease: An observational clinical study
【2h】

Long‐term clinical outcome and mortality risks after paclitaxel‐coated balloon angioplasty in patients with peripheral artery disease: An observational clinical study

机译:紫杉醇涂层气球血管成形术后的长期临床结果和死亡率风险外周血疾病患者:观察临床研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug‐eluting devices (DEDs) are usually used as a standard therapy for revascularization in femoropopliteal artery disease. Randomized controlled trails have found that DEDs with paclitaxel result in superior patency rates and decreased target lesion revascularization. A meta‐analysis by Katsanos et al indicated an increased long‐term mortality in patients treated with paclitaxel‐coated devices. The aim of this observational clinical study was to assess the long‐term clinical outcomes and mortality risk after paclitaxel‐coated balloon angioplasty in patients with symptomatic peripheral artery disease.
机译:药物洗脱装置(DED)通常用作股骨质上动脉疾病中血运重建的标准疗法。随机控制迹纵向发现,具有紫杉醇的DED,导致卓越的通用率和目标病变血运重建。 Katsanos等人的荟萃分析表明,用紫杉醇涂层装置治疗的患者的长期死亡率增加。该观察临床研究的目的是评估患有症状外周血患者患者紫杉醇涂层的气球血管成形术后长期临床结果和死亡率风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号